Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ipilimumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Ipilimumab: Sponsors, patents, clinical trial progress

Ipilimumab is an investigational drug.

There have been 426 clinical trials for Ipilimumab. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2013.

The most common disease conditions in clinical trials are Melanoma, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Bristol-Myers Squibb, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are one hundred and fifty-eight US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Ipilimumab
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)Huntsman Cancer InstitutePhase 1/Phase 2
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)OncoImmune, Inc.Phase 1/Phase 2
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsNational Cancer Institute (NCI)Phase 2

See all Ipilimumab clinical trials

Clinical Trial Summary for Ipilimumab

Top disease conditions for Ipilimumab
Top clinical trial sponsors for Ipilimumab

See all Ipilimumab clinical trials

US Patents for Ipilimumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ipilimumab   See Pricing Compositions and methods of tumor treatment utilizing nanoparticles OP NANO CO., LTD. (Taipei, TW) TRENDMED CO., LTD. (Beitou Dist., Taipei, TW)   See Pricing
Ipilimumab   See Pricing Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL)   See Pricing
Ipilimumab   See Pricing Encapsulated agents and methods of making and using thereof University of Georgia Research Foundation, Inc. (Athens, GA)   See Pricing
Ipilimumab   See Pricing Method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor Amgen Inc. (Thousand Oaks, CA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ipilimumab

Drugname Country Document Number Estimated Expiration Related US Patent
Ipilimumab Australia 2016219004 2035-02-13   See Pricing
Ipilimumab Canada 2976526 2035-02-13   See Pricing
Ipilimumab China 107921005 2035-02-13   See Pricing
Ipilimumab European Patent Office 3256110 2035-02-13   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.